{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03571321",
            "orgStudyIdInfo": {
                "id": "IRB17-1110"
            },
            "organization": {
                "fullName": "University of Chicago",
                "class": "OTHER"
            },
            "briefTitle": "Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia",
            "officialTitle": "Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL)",
            "therapeuticArea": [
                "Pediatrics",
                "Oncology and Hematology",
                "Other"
            ],
            "study": "ruxolitinib-and-chemotherapy-in-adolescents-and-young-adults-with-ph-like-acute-lymphoblastic-leukemia"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-05-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-09-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-09-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-06-22",
            "studyFirstSubmitQcDate": "2018-06-26",
            "studyFirstPostDateStruct": {
                "date": "2018-06-27",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-27",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of Chicago",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Incyte Corporation",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL)."
        },
        "conditionsModule": {
            "conditions": [
                "Acute Lymphoblastic Leukemia",
                "ALL, Childhood",
                "ALL"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 15,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Ruxolitinib",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive ruxolitinib in addition to standard chemotherapy.\n\nStandard Chemotherapy Consists of:\n\n* Remission consolidation therapy (lasting 8 weeks)\n* Interim Maintenance (lasting 8 weeks)\n* Delayed Intensification (lasting 8 weeks\n* Maintenance Therapy (12 week courses/84 day cycles lasting 2-3 years)\n\nPrior to study entry, patients must have completed a 4-drug induction therapy regimen with intrathecal chemotherapy (modified Berlin-Frankfurt-M\u00fcnster (aBFM) regimen or equivalent) as per the institution standard of care.",
                    "interventionNames": [
                        "Drug: Ruxolitinib",
                        "Drug: Cyclophosphamide",
                        "Drug: Cytarabine",
                        "Drug: Mercaptopurine",
                        "Drug: Vincristine",
                        "Drug: Pegaspargase",
                        "Drug: Rituximab",
                        "Drug: Methotrexate (Intrathecal Administration)",
                        "Drug: Methotrexate (Intravenous Administration)",
                        "Drug: Dexamethasone",
                        "Drug: Doxorubicin",
                        "Drug: Thioguanine",
                        "Drug: Methotrexate Oral Product"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Ruxolitinib",
                    "description": "Participants will receive one of 3 doses \\[taken by mouth\\] (30 mg, 40 mg, or 50 mg) depending on when they are enrolled to the study.\n\nRemission consolidation regimen:\n\n* Days 1-14 and 29-43\n\nInterim maintenance regimen:\n\n* Days 1-14 and 29-43\n\nDelayed Intensification regimen:\n\n* Days 1-14 and 29-43",
                    "armGroupLabels": [
                        "Ruxolitinib"
                    ],
                    "otherNames": [
                        "Jakafi"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "Remission consolidation regimen:\n\n* 1000 mg/m2 by intravenous infusion (IV) on Day 1 and Day 29\n\nDelayed Intensification regimen:\n\n* 1000 mg/m2 IV on Day 29",
                    "armGroupLabels": [
                        "Ruxolitinib"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cytarabine",
                    "description": "Remission consolidation regimen:\n\n* 75 mg/m2/day IV or subcutaneously (SC) on Days 1-4 (i.e., 4 doses), 8-11, 29-32, and 36-39\n\nDelayed Intensification regimen:\n\n* 75 mg/m2/day IV or SC on Days 29-32 and 36-39",
                    "armGroupLabels": [
                        "Ruxolitinib"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Mercaptopurine",
                    "description": "Taken by mouth.\n\nRemission consolidation regimen:\n\n* 60 mg/m2 on Days 1-14 and 29-42\n\nMaintenance Therapy:\n\n* 75 mg/m2 on Days 1-84",
                    "armGroupLabels": [
                        "Ruxolitinib"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Vincristine",
                    "description": "Remission consolidation regimen:\n\n* 1.5 mg/m2 (maximum 2 mg) IV once per week on Days 15, 22, 43, and 50\n\nInterim maintenance regimen:\n\n* 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 11, 21, 31, and 41\n\nDelayed Intensification regimen:\n\n* 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 8, 15, 43, and 50\n\nMaintenance Therapy:\n\n* 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 29, and 57",
                    "armGroupLabels": [
                        "Ruxolitinib"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pegaspargase",
                    "description": "Remission consolidation regimen:\n\n* 2500 IU/m2 given by intramuscular (IM) injection or IV on Days 15 and 43\n\nInterim maintenance regimen:\n\n* 2500 IU/m2 IM or IV on Days 2 and 22\n\nDelayed Intensification regimen:\n\n* 2500 IU/m2 IM or IV on Day 4 (OR Day 5 OR Day 6) AND Day 43.",
                    "armGroupLabels": [
                        "Ruxolitinib"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Rituximab",
                    "description": "For patients that have cluster of differentiation antigen 20 positive (CD20+) disease only.\n\nRemission consolidation regimen:\n\n* 375 mg/m2 IV on Days 1, 8, 29 and 36\n\nInterim maintenance regimen:\n\n* 375 mg/m2 IV on Days 1 and 11\n\nDelayed Intensification regimen:\n\n* 375 mg/m2 IV on Days 1 and 8",
                    "armGroupLabels": [
                        "Ruxolitinib"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Methotrexate (Intrathecal Administration)",
                    "description": "Drug is given through a needle which is inserted in one of the spaces between the bones in the lower back (intrathecal \\[IT\\] administration).\n\nRemission consolidation regimen:\n\n* 15 mg on Days 1, 8, 15, and 22\n\nInterim maintenance regimen:\n\n* 15 mg on Days 1 and 31\n\nDelayed Intensification regimen:\n\n* 15 mg on Days 1, 29, and 36\n\nMaintenance Therapy:\n\n* 15 mg on Day 1\n* 15 mg on Day 29 (First 4 courses only)",
                    "armGroupLabels": [
                        "Ruxolitinib"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Methotrexate (Intravenous Administration)",
                    "description": "Interim maintenance regimen:\n\n* 100 mg/m2 IV on Days 1, 11, 21, 31, and 41",
                    "armGroupLabels": [
                        "Ruxolitinib"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Dexamethasone",
                    "description": "Taken by mouth or given by IV infusion.\n\nDelayed Intensification regimen:\n\n* 10 mg/m2 per day (divided into 2 doses) on Days 1-7 and 15-21\n\nMaintenance Therapy:\n\n* 6 mg/m2 per day (divided into 2 doses) on Days 1-5, 29-33, and 57-61",
                    "armGroupLabels": [
                        "Ruxolitinib"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Doxorubicin",
                    "description": "Delayed Intensification regimen:\n\n* 25 mg/m2 IV on Days 1, 8, 15",
                    "armGroupLabels": [
                        "Ruxolitinib"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Thioguanine",
                    "description": "Taken by mouth at least 1 hour after evening meal.\n\nDelayed Intensification regimen:\n\n* 60 mg/m2 on Days 29-42",
                    "armGroupLabels": [
                        "Ruxolitinib"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Methotrexate Oral Product",
                    "description": "Taken by mouth.\n\nMaintenance Therapy:\n\n* 20 mg/m2 weekly (on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78)\n* Not given on Day 29 of first 4 courses (on days when IT Methotrexate is given\\]",
                    "armGroupLabels": [
                        "Ruxolitinib"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Feasibility of adding ruxolitinib to a standard-of-care pediatric-based chemotherapy regimen in adolescents and young adult patients as determined by rate of side effects seen when combination is given",
                    "description": "Determined by rate of side effects seen when combination is given",
                    "timeFrame": "24 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Rate of participants that are minimal residual disease (MRD) negative at end of induction therapy",
                    "timeFrame": "4 weeks"
                },
                {
                    "measure": "Overall survival rate",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Event-free survival rate",
                    "timeFrame": "2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Newly diagnosed de novo B-precursor acute lymphoblastic leukemia (ALL) as determined by World Health Organization (WHO) criteria. Patients must have unequivocal diagnosis of precursor B ALL. This includes an institutional immunophenotyping report that is to assign B-lineage or T-lineage.\n* \"Ph-like\" signature, as determined by low density micro-array (LDA) card\n* Jak-targetable genetic signature as defined by any of the following:\n\n  * Cytokine receptor-like factor 2 (CRLF2) rearranged (JAK2 mutant or wild-type)\n  * JAK2 or erythropoietin receptor (EPOR) fusions.\n  * Other JAK pathway alterations at the discretion of the principle investigator including, but not limited to:\n* SH2B adaptor protein 3 (SH2B3) deletions\n* Interleukin-7 receptor subunit alpha (IL7RA) mutations\n* Prior therapy\n\n  * Prior to starting ruxolitinib, patients must have completed a 4-drug induction regimen with intrathecal chemotherapy (modified aBFM regimen or equivalent) as per the institutional standard of care. Recommended induction treatment is outlined in Section 5.1.2.\n  * No additional prior therapy for acute leukemia except emergency therapy (corticosteroids or hydroxyurea) for blast cell crisis, superior vena cava syndrome, or renal failure due to leukemic infiltration of the kidneys. When indicated, leukapheresis or exchange transfusion is recommended to reduce the white blood cell count (WBC).\n  * Screening may occur at any point prior to or during induction therapy\n* Age \u2265 18 years and \\< 40 years. Because this is specifically a study of the adolescent and young adult population and no adverse event data are currently available on the use of this pediatric-based chemotherapy regimen in patients \u2265 40 years of age, older adults are excluded from this study, but may be eligible for future trials.\n* Eastern Cooperative Oncology Group (ECOG) performance status \u22642 (Karnofsky \u2265 60%)\n* Platelet count \\> 25,000/uL.\n* Patients must have normal organ function as defined below:\n\n  * total bilirubin \u2264 2 mg/dL\n  * aspartate aminotransferase (AST) / alanine aminotransferase (ALT) \u2264 2.5 \u00d7 institutional upper limit of normal\n  * creatinine within normal institutional limits OR creatinine clearance \u2265 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.\n* Because the therapeutic agents used in this study are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Patients who are receiving any other investigational agent.\n* Patients with a \"currently active\" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a \"currently active\" malignancy if they have completed therapy and are free of disease for \u2265 3 years.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or other agents used in study.\n* Use of any potent cytochrome P450 (CYP) 3A4 inhibitor or inducer within 5 half-lives before the first dose of the study drug. Potent inhibitors of CYP3A4 include systemic ketoconazole, posaconazole, voriconazole, clarithromycin, itraconazole, nefazodone, and telithromycin. At the fluconazole dose of 200mg daily used this regimen, there is minimal inhibition of CYP3A4 \\[36\\] and therefore fluconazole is not prohibited on this trial and no dose modifications should be made in the presence of fluconazole.\n\nBecause the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list such as http://medicine.iupui.edu/clinpharm/ddis/table.aspx; medical reference texts such as the Physicians' Desk Reference may also provide this information. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product.\n\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because ruxolitinib is a class C agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ruxolitinib breastfeeding should be discontinued if the mother is treated with ruxolitinib. These potential risks may also apply to other agents used in this study.\n* Down Syndrome due to the likelihood of excessive toxicity resulting. These patients should be treated in consultation with a pediatric oncologist.\n* Burkitt type leukemia\n* Ph+ ALL at time of diagnosis",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "39 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Trials Office",
                    "role": "CONTACT",
                    "phone": "1-855-702-8222",
                    "email": "cancerclinicaltrials@bsd.uchicago.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Wendy Stock, MD",
                    "affiliation": "University of Chicago",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Chicago Medical Center",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60637",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Howie Weiner",
                            "role": "CONTACT",
                            "phone": "773-702-2084",
                            "email": "hweiner@medicine.bsd.uchicago.edu"
                        },
                        {
                            "name": "Wendy Stock, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                },
                {
                    "id": "D000054198",
                    "term": "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
                },
                {
                    "id": "D000007945",
                    "term": "Leukemia, Lymphoid"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M27585",
                    "name": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
                    "asFound": "Acute Lymphoblastic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "asFound": "Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10951",
                    "name": "Leukemia, Lymphoid",
                    "asFound": "Lymphoblastic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T175",
                    "name": "Acute Lymphoblastic Leukemia",
                    "asFound": "Acute Lymphoblastic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3533",
                    "name": "Lymphoblastic Lymphoma",
                    "asFound": "Acute Lymphoblastic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1134",
                    "name": "Childhood Acute Lymphoblastic Leukemia",
                    "asFound": "ALL, Childhood",
                    "relevance": "HIGH"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003561",
                    "term": "Cytarabine"
                },
                {
                    "id": "D000003907",
                    "term": "Dexamethasone"
                },
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "D000069283",
                    "term": "Rituximab"
                },
                {
                    "id": "D000004317",
                    "term": "Doxorubicin"
                },
                {
                    "id": "D000008727",
                    "term": "Methotrexate"
                },
                {
                    "id": "D000014750",
                    "term": "Vincristine"
                },
                {
                    "id": "D000015122",
                    "term": "Mercaptopurine"
                },
                {
                    "id": "C000042705",
                    "term": "Pegaspargase"
                },
                {
                    "id": "D000013866",
                    "term": "Thioguanine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000893",
                    "term": "Anti-Inflammatory Agents"
                },
                {
                    "id": "D000000932",
                    "term": "Antiemetics"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000005765",
                    "term": "Gastrointestinal Agents"
                },
                {
                    "id": "D000005938",
                    "term": "Glucocorticoids"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000000903",
                    "term": "Antibiotics, Antineoplastic"
                },
                {
                    "id": "D000059005",
                    "term": "Topoisomerase II Inhibitors"
                },
                {
                    "id": "D000059003",
                    "term": "Topoisomerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000000020",
                    "term": "Abortifacient Agents, Nonsteroidal"
                },
                {
                    "id": "D000000019",
                    "term": "Abortifacient Agents"
                },
                {
                    "id": "D000012102",
                    "term": "Reproductive Control Agents"
                },
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000003879",
                    "term": "Dermatologic Agents"
                },
                {
                    "id": "D000005493",
                    "term": "Folic Acid Antagonists"
                },
                {
                    "id": "D000019384",
                    "term": "Nucleic Acid Synthesis Inhibitors"
                },
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7492",
                    "name": "Doxorubicin",
                    "asFound": "Cognitive",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17495",
                    "name": "Vincristine",
                    "asFound": "Phase I",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7102",
                    "name": "Dexamethasone",
                    "asFound": "High",
                    "relevance": "HIGH"
                },
                {
                    "id": "M235549",
                    "name": "Dexamethasone acetate",
                    "relevance": "LOW"
                },
                {
                    "id": "M251156",
                    "name": "Pegaspargase",
                    "asFound": "Scenario",
                    "relevance": "HIGH"
                },
                {
                    "id": "M373",
                    "name": "Rituximab",
                    "asFound": "Infusion",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6766",
                    "name": "Cytarabine",
                    "asFound": "Delivered",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11703",
                    "name": "Methotrexate",
                    "asFound": "Under",
                    "relevance": "HIGH"
                },
                {
                    "id": "M227339",
                    "name": "Liposomal doxorubicin",
                    "relevance": "LOW"
                },
                {
                    "id": "M17853",
                    "name": "Mercaptopurine",
                    "asFound": "Threshold",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16628",
                    "name": "Thioguanine",
                    "asFound": "Peripheral nerve",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M4217",
                    "name": "Anti-Inflammatory Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4251",
                    "name": "Antiemetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M8881",
                    "name": "Gastrointestinal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M9047",
                    "name": "Glucocorticoids",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4224",
                    "name": "Antibiotics, Antitubercular",
                    "relevance": "LOW"
                },
                {
                    "id": "M29348",
                    "name": "Topoisomerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M7074",
                    "name": "Dermatologic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M17546",
                    "name": "Vitamin B Complex",
                    "relevance": "LOW"
                },
                {
                    "id": "M8618",
                    "name": "Folic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "M8619",
                    "name": "Folic Acid Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "T446",
                    "name": "Folic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "T447",
                    "name": "Folinic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "T448",
                    "name": "Folate",
                    "relevance": "LOW"
                },
                {
                    "id": "T475",
                    "name": "Vitamin B9",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "AnEm",
                    "name": "Antiemetics"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "Derm",
                    "name": "Dermatologic Agents"
                },
                {
                    "abbrev": "Repr",
                    "name": "Reproductive Control Agents"
                },
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                },
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "Vi",
                    "name": "Vitamins"
                }
            ]
        }
    },
    "hasResults": false
}